Retatrutide and Breastfeeding

Postpartum weight retention affects the majority of women, with many retaining 10-20 pounds or more after pregnancy. For women who entered pregnancy overweight, the additional gain can push BMI into obesity range, increasing health risks for future pregnancies and long-term metabolic health. While the desire to lose weight postpartum is understandable and often medically appropriate, breastfeeding creates a period where pharmaceutical weight loss options are limited. Understanding what is and is not safe during this window is crucial for both maternal and infant health.

Why GLP-1 Medications Are Avoided During Breastfeeding

The contraindication during breastfeeding is based on several factors. It is unknown whether GLP-1 medications pass into breast milk. If the medication does enter breast milk, the effects on infant GI development, appetite regulation, and metabolism are unknown. GLP-1 medications reduce caloric intake and could potentially reduce milk production. Rapid weight loss can mobilize fat-soluble toxins stored in adipose tissue, which can concentrate in breast milk. And nausea and reduced appetite could impair maternal nutrition at a time when nutritional demands are high.

Safe Weight Management While Breastfeeding

During breastfeeding, evidence-based weight management strategies include maintaining a balanced diet with adequate calories (breastfeeding requires approximately 500 extra calories daily), focusing on nutrient density rather than restriction, gentle physical activity as cleared by your OB/GYN (walking, postpartum exercise programs), adequate hydration (breastfeeding increases fluid needs), and patience -- breastfeeding itself burns 300-500 calories daily and supports gradual weight loss.

Restarting Treatment After Weaning

Once breastfeeding is fully discontinued, GLP-1 medications become an option for postpartum weight management. There is no mandatory waiting period after the last nursing session, though discussing timing with your healthcare provider is recommended. Many women find this is an ideal time to start treatment, as the hormonal changes of weaning can actually make weight loss easier. Compounded semaglutide ($99/mo) and tirzepatide ($125/mo) can help address retained pregnancy weight effectively.

Planning Ahead

For women planning pregnancy, the ideal sequence is to achieve a healthy weight before conception using GLP-1 medication if needed, discontinue medication at least 2 months before conception, maintain healthy weight through pregnancy with appropriate weight gain, breastfeed as desired without GLP-1 medication, and restart treatment after weaning if needed to address any retained weight. See our fertility planning guide for more details.